We are excited about the proposed acquisition of Portola announced earlier this week, and look forward to providing additional detail on the trials to expand ANDEXXA's indication, including the Phase II Urgent Surgery program after the transaction closes.On the right side, you can see the design of our trial, which will enroll approximately 270 COVID-19 patients suffering from severe pneumonia or acute respiratory distress syndrome, ARDS, randomized 2:1 versus best supportive care, including allowing the background use of other drugs.